Emergent BioSolutions Inc. - Form 8-K Summary
Business Context and Reporting Period
Emergent BioSolutions Inc. filed this Current Report on Form 8-K on October 2, 2017, regarding events occurring on September 29, 2017. The filing details the entry into a new senior secured credit facility and the termination of a prior credit agreement.
Key Financial Metrics and Facility Terms
- Facility Size: Revolving credit facility of up to $200 million.
- Utilization: No borrowings were made under the facility on the closing date.
- Interest Rates: Eurocurrency rate plus 1.50% to 2.50% or Base Rate plus 0.50% to 1.50%, dependent on the consolidated net leverage ratio.
- Commitment Fees: Ranging from 0.250% to 0.400% per annum on unused commitments.
- Maturity Date: September 29, 2022, subject to a "springing maturity" provision if Convertible Senior Notes due 2021 exceed $25 million in principal on October 20, 2020.
- Financial Covenants: Minimum consolidated debt service coverage ratio of 2.50 to 1.00; Maximum consolidated net leverage ratio of 3.50 to 1.00 (adjustable to 4.00 to 1.00 for four quarters following a permitted acquisition).
Material Changes
The Company terminated its previous Credit Agreement dated December 11, 2013, with Bank of America, N.A., to replace it with the new facility administered by Wells Fargo Bank, National Association. The new agreement provides for a $200 million revolving facility, whereas the specific terms of the terminated facility are not detailed in this text other than its termination.
Outlook, Risks, and Contingencies
The facility is intended for working capital, permitted acquisitions, capital expenditures, and general corporate purposes. The agreement includes significant events of default, including mandatory product recalls exceeding a specified sale price threshold and situations where greater than 50% of federal government accounts receivable are past due for more than 90 days. The facility is secured by a first priority security interest in substantially all assets of the Borrower and its subsidiaries, excluding real property and certain other assets.
Investor Verification Checklist
- Verify the current status of the 2.875% Convertible Senior Notes due 2021 to assess the risk of the "springing maturity" provision accelerating the credit facility's end date.
- Review the full text of the Credit Agreement (Exhibit 10) for specific definitions of "permitted acquisitions" and the exact thresholds for product recall defaults.
- Confirm the Company's current consolidated net leverage ratio to determine the applicable interest rate margin and commitment fee.
- Assess the Company's accounts receivable aging from federal government contracts to evaluate compliance with the 90-day past due covenant.